Furthermore, treatment of tumor-bearing mice with PPARδ inhibitor could efficiently diminish the number and function of IL-10+ Bregs, and act synergistically with anti-CD40 or anti-PD1 antibody to improve antitumor immune responses. Here, IL10 is linked to neoplasm.